Bharat Biotech's Covaxin led to 'enhanced immune responses' in phase 1 trials, says Lancet
Updated : January 22, 2021 04:06 PM IST
The report was an interim one and does not determine the long-term safety outcomes or efficacy of the vaccine
On January 3, Covaxin became the country’s first indigenously produced vaccine against COVID-19 to get ‘restricted emergency approval’.
Published : January 22, 2021 04:06 PM IST